Trexquant Investment’s Harvard Bioscience HBIO Stock Holding History

Trexquant Investment’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,407	Closed	-$87K	–	1559
2022 Q2	$87K	Sell	2,407 -3,912	-62%	-$177K	﹤0.01%	1445
2022 Q1	$392K	Buy	6,319 +4,278	+210%	+$253K	0.02%	881
2021 Q4	$144K	Buy	+2,041	New	+$145K	0.01%	1195
2021 Q2	–	Sell	-1,395	Closed	-$76K	–	1256
2021 Q1	$76K	Buy	+1,395	New	+$67.9K	0.01%	1070
2018 Q4	–	Sell	-1,708	Closed	-$90K	–	1134
2018 Q3	$90K	Buy	+1,708	New	+$95.9K	0.01%	901

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Trexquant Investment's HBIO Position: Q3 2022 in Review

Trexquant Investment sold out of Harvard Bioscience (HBIO) in Q3 2022, closing a stake of 2,407 shares — an estimated $87K sold.

Trexquant Investment first reported a position in HBIO in Q3 2018 and held it in 5 quarters. The position peaked at $392K in Q1 2022. 79 funds tracked by Wall St. Rank hold HBIO as of Q3 2022.

Trexquant Investment reported no remaining Harvard Bioscience position as of Q3 2022 after selling out during the quarter.
Trexquant Investment sold 2,407 Harvard Bioscience shares in Q3 2022, an estimated $87K.
Trexquant Investment first reported a position in Harvard Bioscience in Q3 2018 and held it in 5 quarters.
Trexquant Investment's Harvard Bioscience position peaked at $392K in Q1 2022.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2022.

Based on Trexquant Investment's 13F filing for Q3 2022, filed 14 Nov 2022.